Start Your NewsReadery Pro FREE TRIAL!

Register and verify your email address to start your NewsReadery Pro FREE TRIAL today!

Login / Register

cnbc.com / Share Newsitem

View, share or embed this newsitem using the details below.
The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.
Continue
Please wait ...